NO930059L - O-glykosylert ifn-alfa - Google Patents

O-glykosylert ifn-alfa

Info

Publication number
NO930059L
NO930059L NO93930059A NO930059A NO930059L NO 930059 L NO930059 L NO 930059L NO 93930059 A NO93930059 A NO 93930059A NO 930059 A NO930059 A NO 930059A NO 930059 L NO930059 L NO 930059L
Authority
NO
Norway
Prior art keywords
ifn
glycosylert
alfa
glycosylated
alpha
Prior art date
Application number
NO93930059A
Other languages
English (en)
Other versions
NO930059D0 (no
Inventor
Guenther Adolf
Adolf Himmler
Horst Johann Ahorn
Inge Kalsner
Ingrid Maurer-Fogy
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19904021917 external-priority patent/DE4021917A1/de
Priority claimed from DE19904035877 external-priority patent/DE4035877A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO930059D0 publication Critical patent/NO930059D0/no
Publication of NO930059L publication Critical patent/NO930059L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Formålet med den foreliggende oppfinnelse er O-glykosy- lert IFN-a, fremgangsmåter for fremstilling av det, så vel som anvendelse av de 0-glykosylerte proteiner som legemidler.
NO93930059A 1990-07-10 1993-01-08 O-glykosylert ifn-alfa NO930059L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19904021917 DE4021917A1 (de) 1990-07-10 1990-07-10 Glykosyliertes ifnalpha
DE19904035877 DE4035877A1 (de) 1990-11-12 1990-11-12 O-glycosyliertes ifn-alfa2
PCT/EP1991/001266 WO1992001055A1 (de) 1990-07-10 1991-07-06 O-glycosyliertes ifn-alpha

Publications (2)

Publication Number Publication Date
NO930059D0 NO930059D0 (no) 1993-01-08
NO930059L true NO930059L (no) 1993-01-08

Family

ID=25894855

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930059A NO930059L (no) 1990-07-10 1993-01-08 O-glykosylert ifn-alfa

Country Status (16)

Country Link
EP (1) EP0538300B1 (no)
JP (1) JPH06502987A (no)
KR (1) KR930701601A (no)
AT (1) ATE104348T1 (no)
AU (1) AU650893B2 (no)
CA (1) CA2084514A1 (no)
CZ (1) CZ386392A3 (no)
DE (1) DE59101397D1 (no)
DK (1) DK0538300T3 (no)
ES (1) ES2063515T3 (no)
FI (1) FI930058A0 (no)
HU (1) HUT65846A (no)
NO (1) NO930059L (no)
PL (1) PL297610A1 (no)
SK (1) SK386392A3 (no)
WO (1) WO1992001055A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ245771A (en) * 1992-02-07 1994-08-26 New England Medical Center Inc Mammalian gastrin/cholecystokinin b (cck-b) receptor and antagonists
US5541071A (en) * 1992-02-07 1996-07-30 New England Medical Center Hospitals, Inc. Assay for identifying antagonists of gastrin and CCK-B receptors
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
AU713611B2 (en) * 1994-10-28 1999-12-09 Delft Diagnostic Laboratory B.V. New polynucleic acid sequences for use in the detection and differentiation of prokaryotic organisms
WO1998006863A1 (en) * 1996-08-14 1998-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A vector for polynucleotide vaccines
GB9904695D0 (en) * 1999-03-01 1999-04-21 Imp Cancer Res Tech Peptide
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
ZA200700168B (en) * 2001-10-10 2010-02-24 Novo Nordisk As Remodeling and glycoconjugation of peptides
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
US7803777B2 (en) 2003-03-14 2010-09-28 Biogenerix Ag Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
ES2560657T3 (es) 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
EP1858543B1 (en) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
AR078117A1 (es) 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
MX2010009154A (es) 2008-02-27 2010-09-09 Novo Nordisk As Moleculas conjugadas del factor viii.
WO2014102101A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
EP2938726B1 (en) 2012-12-31 2017-09-27 Boehringer Ingelheim International GmbH Heterologous intron within a signal peptide
RU2610173C1 (ru) * 2016-03-30 2017-02-08 Илья Александрович Марков Рекомбинантная плазмида pFM-IFN-17, обеспечивающая экспрессию интерферона альфа-2b человека, рекомбинантная плазмида pFM-АР, обеспечивающая экспрессию фермента метионинаминопептидазы E. coli, биплазмидный штамм Escherichia coli FM-IFN-АР (pFM-IFN-17, pFM-АР) - продуцент (Met-) рекомбинантного интерферона альфа-2b человека

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN150740B (no) * 1978-11-24 1982-12-04 Hoffmann La Roche
WO1983000693A1 (en) * 1981-08-14 1983-03-03 Berg, Kurt, Frimann SUBJECTS RELATING TO HUMAN INTEFERON-'alpha' SUBTYPE PROTEINS AND CORRESPONDING ANTIBODIES
DE3306060A1 (de) * 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps

Also Published As

Publication number Publication date
FI930058A (fi) 1993-01-08
HUT65846A (en) 1994-07-28
CZ386392A3 (en) 1993-08-11
NO930059D0 (no) 1993-01-08
DK0538300T3 (da) 1994-10-10
EP0538300A1 (de) 1993-04-28
DE59101397D1 (de) 1994-05-19
SK386392A3 (en) 1994-08-10
KR930701601A (ko) 1993-06-12
WO1992001055A1 (de) 1992-01-23
EP0538300B1 (de) 1994-04-13
ES2063515T3 (es) 1995-01-01
AU8208291A (en) 1992-02-04
PL297610A1 (no) 1992-07-13
CA2084514A1 (en) 1992-01-11
HU9300036D0 (en) 1993-04-28
FI930058A0 (fi) 1993-01-08
JPH06502987A (ja) 1994-04-07
ATE104348T1 (de) 1994-04-15
AU650893B2 (en) 1994-07-07

Similar Documents

Publication Publication Date Title
ES2063515T3 (es) Ifn-alfa o-glucosilados.
ID28003A (id) Turunan-turunan adamantana
FI915826A (fi) Farmaceutiska aemnen.
DK1036058T3 (da) Adamantanderivater
ES2036737T3 (es) Procedimiento para la obtencion de mezclas farmaceuticas.
DE69013684D1 (de) Knieprothese.
ITRM920237A1 (it) Perfezionato impiego di medicinali broncodilatatori b2.
NL8901652A (nl) Carboxamideverbindingen, werkwijzen ter bereiding hiervan en farmaceutische preparaten, die deze bevatten.
DE58908155D1 (de) Endoprothese des hüftgelenks.
NO912825L (no) Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper.
NO911429L (no) Stoffbehandling.
NO913360L (no) Fremgangsmaate for fremstilling av syntesegass.
KR900007816A (ko) 사이클로프로필-치환된 아졸릴메틸카비놀, 이의 제조방법 및 약제로서의 이의 용도
NO911430D0 (no) Stoffbehandlingsmetode.
ATE137487T1 (de) Komplexe, enthaltend s(+)-phenyl-alkansäuren und alpha-hydroxy-alkansäuren
NO891574D0 (no) Fremgangsmaate for fremstilling av farmasoeytisk anvendbareforbindelser.
NO892716L (no) Fremgangsmaate for fremstilling av proteiner.
IT9048026A0 (it) Preparato farmaceutico e/o cosmetico.
FR2631230B1 (fr) Lit pliable, notamment pour application medicale
NO891941D0 (no) Fremgangsmaate for fremstilling av cycloalkadiener.
MX9203129A (es) Proteinas bmp-5.
SE9002274D0 (sv) Novel 3,3'-dithiobis(propionic esters).
MX9203467A (es) Derivados de peptidos.
NO871013D0 (no) Farmasoeytisk artikkel og fremgangsmaate for fremstilling derav.
ATE92106T1 (de) Polypeptid und dessen herstellung.